Yu-Jung Wei1, Linda Simoni-Wastila2, Jennifer S Albrecht3, Ting-Ying Huang2, Patience Moyo2, Bilal Khokhar2, Ilene Harris4, Patricia Langenberg3, Giora Netzer5, Susan W Lehmann6. 1. Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, Florida, USA. 2. Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, Maryland, USA. 3. Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, USA. 4. IMPAQ International LLC, Columbia, Maryland, USA. 5. Division of Pulmonary and Critical Care Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA. 6. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Abstract
The effect of treating comorbid depression to achieve optimal management of chronic obstructive pulmonary disease (COPD) has not yet empirically tested. We examined the association between antidepressant treatment and use of and adherence to COPD maintenance medications among patients with new-onset COPD and comorbid depression. METHODS: Using 2006-2012 Medicare data, this retrospective cohort study identified patients with newly diagnosed COPD and new-onset major depression. Two exposures-antidepressant use (versus non-use) and adherence measured by proportion of days covered (PDC) (PDC ≥0.8 versus <0.8)-were assessed quarterly. We used marginal structural models to estimate the effects of prior antidepressant use and adherence on subsequent COPD maintenance inhaler use and adherence outcomes, accounting for time-varying confounders. RESULTS: A total of 25 458 COPD-depression patients, 82% with antidepressant treatment, were followed for a median of 2.5 years. Nearly half (48%) used at least 1 COPD maintenance inhaler in any given quarter; among users, 3 in 5 (61%) had a PDC of <0.8. Compared to patients with no antidepressant treatment, those with antidepressant use were more likely to use (relative ratio [RR] = 1.15, 95% confidence interval [CI] = 1.12- 1.17) and adhere to (RR = 1.08, 95% = 1.03-1.14) their COPD maintenance inhalers. Patients who adhered to antidepressant treatment were more likely to use and adhere to COPD maintenance inhalers. CONCLUSION: Regularly treated depression may increase use of and adherence to necessary maintenance medications for COPD. Antidepressant treatment may be a key determinant to improving medication-taking behaviors among COPD patients comorbid with depression.
The effect of treating comorbid depression to achieve optimal management of chronic obstructive pulmonary disease (COPD) has not yet empirically tested. We examined the association between antidepressant treatment and use of and adherence to COPD maintenance medications among patients with new-onset COPD and comorbid depression. METHODS: Using 2006-2012 Medicare data, this retrospective cohort study identified patients with newly diagnosed COPD and new-onset major depression. Two exposures-antidepressant use (versus non-use) and adherence measured by proportion of days covered (PDC) (PDC ≥0.8 versus <0.8)-were assessed quarterly. We used marginal structural models to estimate the effects of prior antidepressant use and adherence on subsequent COPD maintenance inhaler use and adherence outcomes, accounting for time-varying confounders. RESULTS: A total of 25 458 COPD-depressionpatients, 82% with antidepressant treatment, were followed for a median of 2.5 years. Nearly half (48%) used at least 1 COPD maintenance inhaler in any given quarter; among users, 3 in 5 (61%) had a PDC of <0.8. Compared to patients with no antidepressant treatment, those with antidepressant use were more likely to use (relative ratio [RR] = 1.15, 95% confidence interval [CI] = 1.12- 1.17) and adhere to (RR = 1.08, 95% = 1.03-1.14) their COPD maintenance inhalers. Patients who adhered to antidepressant treatment were more likely to use and adhere to COPD maintenance inhalers. CONCLUSION: Regularly treated depression may increase use of and adherence to necessary maintenance medications for COPD. Antidepressant treatment may be a key determinant to improving medication-taking behaviors among COPDpatients comorbid with depression.
Authors: J G van Manen; P J Bindels; C J IJzermans; J S van der Zee; B J Bottema; E Schadé Journal: J Clin Epidemiol Date: 2001-03 Impact factor: 6.437
Authors: Mark E Kunik; Kent Roundy; Connie Veazey; Julianne Souchek; Peter Richardson; Nelda P Wray; Melinda A Stanley Journal: Chest Date: 2005-04 Impact factor: 9.410
Authors: Teresa L Kramer; Richard R Owen; Dale Cannon; Kevin L Sloan; Carol R Thrush; D Keith Williams; Mark A Austen Journal: Jt Comm J Qual Saf Date: 2003-09
Authors: Elizabeth H B Lin; Wayne Katon; Michael Von Korff; Carolyn Rutter; Greg E Simon; Malia Oliver; Paul Ciechanowski; Evette J Ludman; Terry Bush; Bessie Young Journal: Diabetes Care Date: 2004-09 Impact factor: 19.112
Authors: M Alan Brookhart; Amanda R Patrick; Colin Dormuth; Jerry Avorn; William Shrank; Suzanne M Cadarette; Daniel H Solomon Journal: Am J Epidemiol Date: 2007-05-15 Impact factor: 4.897
Authors: Louise Foley; James Larkin; Richard Lombard-Vance; Andrew W Murphy; Lisa Hynes; Emer Galvin; Gerard J Molloy Journal: BMJ Open Date: 2021-09-02 Impact factor: 3.006